Tafamidis for treating transthyretin amyloidosis with cardiomyopathy (TA696)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 12 May 2021
Tafamidis for treating transthyretin amyloidosis with cardiomyopathy [ID6327]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 12 June 2024
Acoramidis for treating transthyretin-mediated amyloidosis cardiomyopathy TS ID 11904Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC